Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the potential future utility of PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the future for evaluating PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the role for PD-L1 expression as a biomarker for treatment response in EGFR-mutant NSCLC.

Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.

Manish A. Shah, MD, discusses the PFS benefit with zanidatamab plus chemotherapy with/without tislelizumab in HER2-positive GEA regardless of PD-L1 status.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.

Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses efficacy data with RP1 plus nivolumab in patients with melanoma who had progressed on PD-1–directed therapy.

Peter Martin, MD, discusses the current role of BTK inhibitors in MCL and how future research may solidify the use of these agents in this disease.

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

Joseph M. Scandura, MD, PhD, discusses the phase 2 SENTRY-2 study evaluating single-agent selinexor in JAK inhibitor–naive myelofibrosis.

Justin Kaner, MD, discusses the latest advances surrounding menin inhibitors in acute myeloid leukemia.

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.

Highlighting recent clinical trial data on pirtobrutinib in patients with chronic lymphocytic leukemia, the panel shares their experience utilizing it in clinical practice.

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.

John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.

Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Pooja Murthy, MD, discusses second-line treatments in ER+/HER2– metastatic breast cancer for patients following progression on endocrine therapy plus a CDK4/6 inhibitor.